A Study to Evaluate ONM-100 an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

  • days left to enroll
  • participants needed
  • sponsor
    OncoNano Medicine, Inc.
Updated on 29 January 2021
breast cancer
squamous cell carcinoma
lung cancer
solid tumour
ovarian cancer
squamous cell carcinoma of head and neck
colorectal neoplasm
cancer of the ovary
lung carcinoma


This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine surgery.

Condition Malignant neoplasm of prostate, Non-Small Cell Lung Cancer, Ovarian disorder, Colorectal Cancer, Rectal disorder, Prostatic disorder, Breast Cancer, Ovarian Cancer, Transitional cell carcinoma, Prostate Disorders, Colon Cancer Screening, Prostate Cancer, Early, Recurrent, Rectal Disorders, Colon cancer; rectal cancer, Ovarian Function, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer Diagnosis, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Recurrent Ovarian Cancer, Prostate Cancer, Urothelial Carcinoma, breast carcinoma, colorectal neoplasm, prostate carcinoma, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, cancer, breast, colorectal cancers, nsclc, ovarian tumors, prostate cancers, cancer, colorectal, colorectal tumor, tumors, colorectal
Treatment ONM-100
Clinical Study IdentifierNCT03735680
SponsorOncoNano Medicine, Inc.
Last Modified on29 January 2021


Yes No Not Sure

Inclusion Criteria

Biopsy-confirmed diagnosis of primary or recurrent respective tumor type and scheduled to undergo surgical resection
Part 1: Biopsy-confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC) or breast cancer
Part 2: Biopsy-confirmed diagnosis of HNSCC, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, urothelial carcinoma and non-small cell lung cancer
Part 3: Stage 2 to 4 HNSCC Including T0 or Tx unknown Primary cancers

Exclusion Criteria

Histologically diagnosed by an excisional biopsy procedure
Tumors at sites of which the surgeon would assess that in vivo intraoperative imaging would not be feasible
Life expectancy <12 weeks
Hepatic impairment (Child-Pugh score >5) or significant liver disease including active hepatitis or cirrhosis
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note